//
sign in
Profile
by @danabra.mov
Profile
by @dansshadow.bsky.social
Profile
by @jimpick.com
AviHandle
by @danabra.mov
AviHandle
by @dansshadow.bsky.social
AviHandle
by @katherine.computer
EventsList
by @katherine.computer
ProfileHeader
by @dansshadow.bsky.social
ProfileHeader
by @danabra.mov
ProfileMedia
by @danabra.mov
ProfilePlays
by @danabra.mov
ProfilePosts
by @danabra.mov
ProfilePosts
by @dansshadow.bsky.social
ProfileReplies
by @danabra.mov
Record
by @atsui.org
Skircle
by @danabra.mov
StreamPlacePlaylist
by @katherine.computer
+ new component
ProfilePosts









Loading...
@dkfz.bsky.social @uniheidelberg.bsky.social @neurooncologyhd.bsky.social @eanoassociation.bsky.social @nct-heidelberg.bsky.social @natureportfolio.nature.com
7/7 Huge thanks for my co-first authors Darui Jin and Artem Shmatko, and senior authors Felix Sahm and @moritzgerstung.bsky.social, and all collaborators ❤️ Read in Nature Cancer: www.nature.com/articles/s43...
6/n Why does it matter?? Hetairos can streamline diagnostics, streamline which cases need molecular testing and most importantly- bring up-to-date subtyping to centres where methylation profiling is simply not available. It’s about making precision diagnostics accessible to all 🌏
2/n The problem- methylation profiling gives the most granular CNS tumour classification (also recommended by WHO, NCCN, etc), but it’s expensive and takes ~2 weeks H&E slides are everywhere, fast and cheap, but can’t deliver that detail on their own 🔬 Hetairos bridges that gap 🌉